Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 51.00M | 44.64M | 38.79M | 33.30M | 30.91M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 51.00M | 44.64M | 38.79M | 33.30M | 30.91M |
| Cost of Revenue | 3.96M | 3.76M | 2.67M | 3.37M | 3.01M |
| Gross Profit | 47.04M | 40.88M | 36.12M | 29.94M | 27.91M |
| SG&A Expenses | 52.43M | 46.91M | 40.50M | 39.26M | 39.49M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 56.59M | 50.93M | 43.45M | 42.98M | 42.90M |
| Operating Income | -5.59M | -6.28M | -4.66M | -9.68M | -11.98M |
| Income Before Tax | -8.27M | -9.64M | -6.58M | -11.67M | -14.07M |
| Income Tax Expenses | 106.00K | 106.00K | 365.00K | 365.00K | 365.00K |
| Earnings from Continuing Operations | -8.38 | -9.74 | -6.94 | -12.04 | -14.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.38M | -9.74M | -6.94M | -12.04M | -14.44M |
| EBIT | -5.59M | -6.28M | -4.66M | -9.68M | -11.98M |
| EBITDA | -5.49M | -6.18M | -4.56M | -9.58M | -11.88M |
| EPS Basic | -0.28 | -0.33 | -0.25 | -0.44 | -0.53 |
| Normalized Basic EPS | -0.14 | -0.17 | -0.15 | -0.26 | -0.32 |
| EPS Diluted | -0.28 | -0.33 | -0.26 | -0.45 | -0.54 |
| Normalized Diluted EPS | -0.14 | -0.17 | -0.15 | -0.26 | -0.32 |
| Average Basic Shares Outstanding | 121.06M | 114.31M | 110.59M | 110.07M | 109.71M |
| Average Diluted Shares Outstanding | 122.28M | 114.31M | 110.59M | 110.07M | 109.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |